S. Hartsel, J. Bolard, and B. Amphotericin, New life for an old drug, Trends Pharmacol. Sci, vol.17, pp.445-449, 1996.

F. Reichenberger, J. M. Habicht, A. Gratwohl, and M. Tamm, Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients, Eur. Respir. J, vol.19, pp.743-755, 2001.

C. Wu and L. Z. Benet, Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res, vol.22, pp.11-23, 2005.

J. J. Torrado, R. Espada, M. P. Ballesteros, and S. Torrado-santiago, Amphotericin B formulations and drug targeting, J. Pharm. Sci, vol.97, pp.2405-2425, 2008.

Y. Zu, W. Sun, X. Zhao, W. Wang, Y. Li et al., Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation

, Eur. J. Pharm. Sci, vol.53, pp.109-117, 2014.

V. K. Prajapati, K. Awasthi, T. P. Yadav, M. Rai, O. N. Srivastava et al., An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes Is an Effective Treatment for Experimental Visceral Leishmaniasis, J. Infect. Dis, vol.205, p.235, 2012.

K. Singh, A. K. Tiwary, and V. Rana, Spray dried chitosan-EDTA superior microparticles as solid substrate for the oral delivery of amphotericin B, Int. J. Biol. Macromol, vol.58, pp.310-319, 2013.

Z. Yang, M. Chen, M. Yang, J. Chen, W. Fang et al., Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection, Int. J. Nanomed, vol.9, pp.327-336, 2014.

E. K. Wasan, K. Bartlett, P. Gershkovich, O. Sivak, B. Banno et al., Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans, Int. J. Pharm, vol.372, pp.76-84, 2009.

S. Jain, P. U. Valvi, N. K. Swarnakar, and K. Thanki, Gelatin Coated Hybrid Lipid Nanoparticles for Oral Delivery of Amphotericin B, Mol. Pharm, vol.9, pp.2542-2553, 2012.

J. L. Italia, M. N. Kumar, and K. C. Carter, Evaluating the Potential of Polyester Nanoparticles for Per Oral Delivery of Amphotericin B in Treating Visceral Leishmaniasis, J. Biomed. Nanotechnol, vol.8, pp.695-702, 2012.

C. Zhang, C. Gu, F. Peng, W. Liu, J. Wan et al., Preparation and Optimization of Triptolide-Loaded Solid Lipid Nanoparticles for Oral Delivery with Reduced Gastric Irritation, Molecules, vol.18, pp.13340-13356, 2013.

M. Skiba-lahiani, F. Hallouard, L. Mehenni, H. Fessi, and M. Skiba, Development and characterization of oral liposomes of vegetal ceramide based amphotericin B having enhanced dry solubility and solubility
URL : https://hal.archives-ouvertes.fr/hal-02143703

, Mater. Sci. Eng. C Mater. Biol. Appl, vol.48, pp.145-149, 2015.

K. V. Clemons and D. A. Stevens, Comparative Efficacies of Four Amphotericin B Formulations-Fungizone, AmBisome, and Abelcet-Against Systemic Murine Aspergillosis, vol.48, pp.1047-1050, 2004.

R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M. P. Ballesteros et al., Effect of aggregation state on the toxicity of different amphotericin B preparations, Int. J. Pharm, vol.361, pp.64-69, 2008.

W. Tiyaboonchai and N. Limpeanchob, Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles, Int. J. Pharm, vol.329, pp.142-149, 2007.

F. Hallouard, L. Mehenni, M. Lahiani-skiba, Y. Anouar, and M. Skiba, Solid Dispersions for Oral Administration: An Overview of the Methods for their Preparation, Curr. Pharm. Des, vol.22, pp.4942-4958, 2016.

M. Skiba and M. Lahiani-skiba, Novel method for preparation of cyclodextrin polymers: Physico-chemical characterization and cytotoxicity, J. Incl. Phenom. Macrocycl. Chem, vol.75, pp.341-349, 2013.

D. Mathpal, T. Garg, G. Rath, and A. K. Goyal, Development and characterization of spray dried microparticles for pulmonary delivery of antifungal drug, Curr. Drug Deliv, vol.12, pp.464-471, 2015.

T. Higuchi and K. A. Connors, A phase solubility technique, Adv. Anal. Chem. Inst, vol.4, pp.117-211, 1965.

T. Boukhris, M. Lahiani-skiba, D. Martin, and M. Skiba, Novel oral Formulation of cyclosporine-spray-dried dispersion using cyclodextrin terpolymers, J. Incl. Phenom. Macrocycl. Chem, vol.75, pp.323-332, 2013.

M. R. Marques, R. Loebenberg, and M. Almukainzi, Simulated Biological Fluids with Possible Application in Dissolution Testing. Dissolution Technol, vol.18, pp.15-28, 2011.

, Validation of Analytical Procedures: Text and Methodology, p.12, 2005.

M. Gago´sgago´s and M. Arczewska, Spectroscopic studies of molecular organization of antibiotic amphotericin B in monolayers and dipalmitoylphosphatidylcholine lipid multibilayers, Biochim. Biophys. Acta Biomembr, vol.11, pp.2124-2130, 2010.

N. A. Al-assady, E. S. Ali, and I. M. Alrubayae, Preparation, Characterization and Evaluation of Controlled Release Microspheres Containing Amphotericin B, J. Basrah Res, vol.39, pp.114-131, 2013.

S. Fatmi, L. Bournine, M. Iguer-ouada, M. Lahiani-skiba, F. Bouchal et al., Amorphous solid dispersion studies of camptothecin-cyclodextrin inclusion complexes in PEG 6000, Acta Pol. Pharm, vol.72, pp.179-192, 2015.

D. Butani, C. Yewale, and A. Misra, Topical Amphotericin B solid lipid nanoparticles: Design and development, Colloids Surf. B Biointerfaces, vol.139, pp.17-24, 2016.

M. R. Bunow and I. W. Levin, Vibrational raman spectra of lipid systems containing amphotericin B, Biochim. Biophys. Acta Biomembr, vol.464, pp.202-216, 1977.

, Pharmaceutics, vol.10, p.235, 2018.

M. Gago´sgago´s, D. Kamí-nski, M. Arczewska, B. Krajnik, and S. Ma´ckowskima´ckowski, Spectroscopic evidence for self-organization of N-iodoacetylamphotericin B in crystalline and amorphous phases, J. Phys. Chem. B, vol.116, pp.12706-12713, 2012.

Y. Chen, S. Wang, S. Wang, C. Liu, C. Su et al., Initial Drug Dissolution from Amorphous Solid Dispersions Controlled by Polymer Dissolution and Drug-Polymer Interaction, Pharm. Res, vol.33, pp.2445-2458, 2016.

K. N. Gangadhar, K. Adhikari, and T. Srichana, Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation, Int. J. Pharm, vol.471, pp.430-438, 2014.

J. Barwicz, S. Christian, and I. Gruda, Effects of the aggregation state of amphotericin B on its toxicity to mice, Antimicrob. Agents Chemother, vol.36, pp.2310-2315, 1992.

J. Mazerski, J. Bolard, and E. Borowski, Effect of the modifications of ionizable groups of amphotericin B on its ability to form complexes with sterols in hydroalcoholic media, Biochim. Biophys. Acta BBA Biomembr, vol.1236, pp.170-176, 1995.

J. Mazerski, J. Grzybowska, E. Borowski, J. Nska, M. Wieczór et al., Influence of net charge on the aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media, Eur. Biophys. J. EBJ, vol.18, pp.159-164, 1990.

N. Rajagopalan, S. C. Chen, and W. Chow, A study of the inclusion complex of amphotericin-B with ?-cyclodextrin, Int. J. Pharm, vol.29, pp.161-168, 1986.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2018 by the authors. Licensee MDPI

D. I. Denning and . Aspergillosis, Clin Infect Dis, vol.26, issue.4, p.781803, 1998.

J. R. Perfect, G. M. Cox, J. Y. Lee, C. A. Kauffman, L. De-repentigny et al., The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.33, issue.11, p.182433, 2001.

S. Chen and T. C. Sorrell, Antifungal agents, Med J Aust, vol.187, issue.7, p.4049, 2007.

J. H. Rex and T. J. Walsh, Editorial Response: Estimating the True Cost of Amphotericin B. Clin Infect Dis, vol.29, p.140810, 1999.

Y. Zu, W. Sun, X. Zhao, W. Wang, Y. Li et al., Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.53, p.10917, 2014.

V. K. Prajapati, K. Awasthi, T. P. Yadav, M. Rai, O. N. Srivastava et al., An oral formulation of amphotericin B attached to functionalized carbon nanotubes is an effective treatment for experimental visceral leishmaniasis, J Infect Dis, vol.205, issue.2, p.3336, 2012.

K. Singh, A. K. Tiwary, and R. V. , Spray dried chitosan-EDTA superior microparticles as solid substrate for the oral delivery of amphotericin B, Int J Biol Macromol, vol.58, p.3109, 2013.

Z. Yang, M. Chen, M. Yang, J. Chen, W. Fang et al., Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection, Int J Nanomedicine, vol.9, p.32736, 2014.

E. K. Wasan, K. Bartlett, P. Gershkovich, O. Sivak, B. Banno et al., Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans, Int J Pharm, vol.372, issue.12, p.7684, 2009.

S. Jain, P. U. Valvi, N. K. Swarnakar, and K. Thanki, Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B. Mol Pharm, vol.9, p.254253, 2012.

J. L. Italia, M. Kumar, and K. C. Carter, Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis, J Biomed Nanotechnol, vol.8, issue.4, p.695702, 2012.

C. Zhang, C. Gu, F. Peng, W. Liu, J. Wan et al., Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. Mol Basel Switz, vol.18, p.1334056, 2013.

D. Mathpal, T. Garg, G. Rath, and A. K. Goyal, Development and characterization of spray dried microparticles for pulmonary delivery of antifungal drug, Curr Drug Deliv, vol.12, issue.4, p.46471, 2015.

S. Hartsel and J. Bolard, Amphotericin B: new life for an old drug, Trends Pharmacol Sci, vol.17, issue.12, p.4459, 1996.

J. J. Torrado, R. Espada, M. P. Ballesteros, and S. Torrado-santiago, Amphotericin B formulations and drug targeting, J Pharm Sci, vol.97, issue.7, p.240525, 2008.

R. Espada, J. M. Josa, S. Valdespina, M. A. Dea, M. P. Ballesteros et al., HPLC assay for determination of amphotericin B in biological samples, Biomed Chromatogr BMC, vol.22, issue.4, p.4027, 2008.

R. Serrano, D. , P. Ballesteros, M. , G. Schätzlein et al., Amphotericin B Formulations The Possibility of Generic Competition. Pharm Nanotechnol, vol.1, p.2508, 2013.

R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M. P. Ballesteros et al., Effect of aggregation state on the toxicity of different amphotericin B preparations, Int J Pharm, vol.361, issue.12, p.649, 2008.

, NCCN practice guidelines for fever and neutropenia. National Comprehensive Cancer Network. Oncol Williston Park N, vol.13, p.197257, 1999.

B. L. Herwaldt and . Leishmaniasis, Lancet Lond Engl, vol.354, issue.9185, p.11919, 1999.

A. Tamiru, B. Tigabu, S. Yifru, E. Diro, and A. Hailu, Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, BMC Infect Dis, vol.16, issue.1, p.548, 2016.

H. W. Murray, Treatment of visceral leishmaniasis in 2004, Am J Trop Med Hyg, vol.71, issue.6, p.78794, 2004.

G. Barratt and S. Bretagne, Optimizing efficacy of Amphotericin B through nanomodification, Int J Nanomedicine, vol.2, issue.3, p.30113, 2007.

V. S. Amato, A. Rabello, A. Rotondo-silva, A. Kono, T. Maldonado et al., Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients, Acta Trop, vol.92, issue.2, p.32, 2004.

K. A. Marr, R. A. Carter, F. Crippa, W. A. Corey, and L. , Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.34, issue.7, p.90917, 2002.

. Netgen, Aspergillose pulmonaire invasive et aspergillose pulmonaire chronique

. Revue-médicale-suisse, , 2017.

T. J. Walsh, E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis et al., Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.46, issue.3, p.32760, 2008.

S. Kawamura, S. Maesaki, K. Tomono, T. Tashiro, and S. Kohno, Clinical evaluation of 61 patients with pulmonary aspergilloma, Intern Med Tokyo Jpn, vol.39, issue.3, p.20912, 2000.

, Aspergilloma and residual tuberculous cavities--the results of a resurvey, Tubercle, vol.51, issue.3, p.22745, 1970.

G. A. Sarosi, P. M. Silberfarb, N. A. Saliba, P. M. Huggin, and F. E. Tosh, Aspergillomas occurring in blastomycotic cavities, Am Rev Respir Dis, vol.104, issue.4, p.5814, 1971.

S. H. Rosenheim and J. Schwarz, Cavitary pulmonary cryptococcosis complicated by aspergilloma, Am Rev Respir Dis, vol.111, issue.4, p.54953, 1975.

A. O. Soubani and P. H. Chandrasekar, The clinical spectrum of pulmonary aspergillosis, Chest, vol.121, issue.6, p.198899, 2002.

C. Duret, Développement et évaluation de poudres sèches pour inhalation à base pulmonaire, 2013.

E. Tsubura, Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma

, Kekkaku, vol.72, issue.10, pp.557-64, 1997.

C. A. Kauffman, Quandary about treatment of aspergillomas persists, Lancet Lond Engl, vol.347, issue.9016, p.1640, 1996.
DOI : 10.1016/s0140-6736(96)91481-6

J. Giron, C. Poey, P. Fajadet, N. Sans, D. Fourcade et al., CT-guided percutaneous treatment of inoperable pulmonary aspergillomas: a study of 40 cases, Eur J Radiol, vol.28, issue.3, p.23542, 1998.

R. Agarwal, A. Chakrabarti, A. Shah, D. Gupta, J. F. Meis et al., Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria, Clin Exp Allergy J Br Soc Allergy Clin Immunol, vol.43, issue.8, p.85073, 2013.

M. Proesmans, F. Vermeulen, M. Vreys, D. Boeck, and K. , Use of nebulized amphotericin B in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis, Int J Pediatr, p.376287, 2010.

A. H. Limper, K. S. Knox, G. A. Sarosi, N. M. Ampel, J. E. Bennett et al., An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients, Am J Respir Crit Care Med, vol.183, issue.1, p.96128, 2011.

M. Kousha, R. Tadi, and A. O. Soubani, Pulmonary aspergillosis: a clinical review, Eur Respir Rev, vol.20, issue.121, p.15674, 2011.
DOI : 10.1183/09059180.00001011

URL : http://err.ersjournals.com/content/20/121/156.full.pdf

G. R. Thompson and T. F. Patterson, Pulmonary aspergillosis. Semin Respir Crit Care Med, vol.29, p.10310, 2008.

R. H. Hruban, M. A. Meziane, E. A. Zerhouni, P. S. Wheeler, J. S. Dumler et al., Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis, J Comput Assist Tomogr, vol.11, issue.3, p.5346, 1987.

T. E. Corcoran, R. Venkataramanan, K. M. Mihelc, A. L. Marcinkowski, J. Ou et al., Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.6, issue.11, p.276573, 2006.

, Lipid Amphotericin B Formulations and the Echinocandins -ppt download, 2018.

D. W. Bates, L. Su, D. T. Yu, G. M. Chertow, D. L. Seger et al., Mortality and costs of acute renal failure associated with amphotericin B therapy, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.32, issue.5, p.68693, 2001.

J. R. Wingard, P. Kubilis, L. Lee, G. Yee, M. White et al., Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.29, issue.6, p.14027, 1999.

C. I. Bagnis and G. Deray, Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transplant Off Publ Saudi Cent Organ Transplant Saudi Arab, vol.13, p.48191, 2002.

R. Laniado-laborín and C. Mn, Amphotericin B: side effects and toxicity, Rev Iberoam Micol, vol.26, issue.4, p.2237, 2009.

P. Buri, F. Puisieux, E. Doelker, and . Benoit-j.-p,

L. Lavoisier, , 2018.

G. Lopez-berestein, G. P. Bodey, V. Fainstein, M. Keating, L. S. Frankel et al., Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med, vol.149, p.25336, 1989.

C. W. Grant, K. S. Hamilton, K. D. Hamilton, and K. R. Barber, Physical biochemistry of a liposomal amphotericin B mixture used for patient treatment, Biochim Biophys Acta, vol.984, issue.1, p.1120, 1989.

R. Janknegt, S. De-marie, I. A. Bakker-woudenberg, and D. J. Crommelin, Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics, Clin Pharmacokinet, vol.23, issue.4, p.27991, 1992.

A. C. Leenders and S. De-marie, The use of lipid formulations of amphotericin B for systemic fungal infections, Leukemia, vol.10, issue.10, p.15705, 1996.

M. Tiphine, V. Letscher-bru, and R. Herbrecht, Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability, Transpl Infect Dis Off J Transplant Soc, vol.1, issue.4, p.27383, 1999.

R. Bowden, P. Chandrasekar, M. H. White, X. Li, L. Pietrelli et al., A doubleblind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.35, issue.4, p.35966, 2002.

J. W. Hiemenz and T. J. Walsh, Lipid Formulations of Amphotericin B: Recent Progress and Future Directions, Clin Infect Dis, vol.22, p.13344, 1996.

J. P. Jain and N. Kumar, Development of amphotericin B loaded polymersomes based on (PEG)(3)-PLA co-polymers: Factors affecting size and in vitro evaluation, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.40, issue.5, p.45665, 2010.

G. Vandermeulen, L. Rouxhet, A. Arien, M. E. Brewster, and V. Préat, Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(epsilon-caprolactone-cotrimethylenecarbonate) polymeric micelles, Int J Pharm, vol.309, issue.12, p.40, 2006.

K. K. Chakraborty and S. R. Naik, Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin -beta complexed with different chemically modified beta -cyclodextrins, J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm, vol.6, issue.2, p.2317, 2003.

P. Longuet, V. Joly, P. Amirault, N. Seta, C. Carbon et al., Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats, Antimicrob Agents Chemother, vol.35, issue.7, pp.1303-1311, 1991.

J. S. Hostetler, K. V. Clemons, L. H. Hanson, and D. A. Stevens, Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis, Antimicrob Agents Chemother, vol.36, issue.12, p.265660, 1992.

G. Wortmann, M. Zapor, R. Ressner, S. Fraser, J. Hartzell et al., Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis, Am J Trop Med Hyg, vol.83, issue.5, p.102833, 2010.

A. Hussain, V. K. Singh, O. P. Singh, K. Shafaat, S. Kumar et al., Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of Amphotericin B. Drug Deliv, vol.23, p.310110, 2016.

, Interaction of amphotericin B with polymeric colloids: A spectroscopic studyScienceDirect, 2017.

M. S. Espuelas, P. Legrand, M. A. Campanero, M. Appel, M. Chéron et al., Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice, J Antimicrob Chemother, vol.52, issue.3, p.41927, 2003.

T. Otsubo, S. Maesaki, M. A. Hossain, Y. Yamamoto, K. Tomono et al., In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus, Antimicrob Agents Chemother, vol.43, issue.3, p.4715, 1999.

M. Nagata, T. Yotsuyanagi, and K. Ikeda, A two-step model of disintegration kinetics of liposomes in bile salts, Chem Pharm Bull (Tokyo), vol.36, issue.4, p.150813, 1988.

T. L. Whateley, Drug Delivery and Targeting; for Pharmacists and Pharmaceutical Scientists, J Drug Target, vol.10, issue.8, p.637637, 2002.

C. Ménez, M. Buyse, M. Besnard, R. Farinotti, P. M. Loiseau et al., Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro, Antimicrob Agents Chemother, vol.50, issue.11, p.3793800, 2006.

M. C. Venier-julienne, I. Vouldoukis, L. Monjour, and J. P. Benoit, In vitro study of the antileishmanial activity of biodegradable nanoparticles, J Drug Target, vol.3, issue.1, p.239, 1995.

R. Kumar, G. C. Sahoo, K. Pandey, V. Das, and P. Das, Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani, Drug Deliv, vol.22, issue.3, p.3838, 2015.

H. M. Mansour, Y. Rhee, and X. Wu, Nanomedicine in pulmonary delivery, Int J Nanomedicine, vol.4, p.299319, 2009.

E. J. Ruijgrok, A. G. Vulto, and E. W. Van-etten, Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats, J Antimicrob Chemother, vol.48, issue.1, p.8995, 2001.

Z. Al-nakeeb, A. Sudan, A. R. Jeans, L. Gregson, J. Goodwin et al., Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration, Antimicrob Agents Chemother, vol.56, issue.8, pp.4146-53, 2012.

V. Paquet and E. M. Carreira, Significant Improvement of Antifungal Activity of Polyene Macrolides by Bisalkylation of the Mycosamine, Org Lett, vol.8, issue.9, p.18079, 2006.

N. R. Mathias and M. A. Hussain, Non-invasive systemic drug delivery: developability considerations for alternate routes of administration, J Pharm Sci, vol.99, issue.1, p.120, 2010.

B. Mukherjee, P. Paul, L. Dutta, S. Chakraborty, M. Dhara et al., Chapter 14 -Pulmonary Administration of Biodegradable Drug Nanocarriers for More Efficacious Treatment of Fungal Infections in Lungs: Insights Based on Recent Findings, Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics, p.26180, 2017.

A. C. Leenders, S. De-marie, M. T. Ten-kate, I. A. Bakker-woudenberg, and H. A. Verbrugh, Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis, J Antimicrob Chemother, vol.38, issue.2, p.21525, 1996.

V. Lê, Influence des propriétés physicochimiques du principe actif et du transporteur sur la performance aérodynamique des mélanges de poudre pour inhalation

C. Warolin, évolution de quinze formes pharmaceutiques, Rev Hist Pharm, vol.85, issue.313, p.804, 1997.

N. Wauthoz, P. Deleuze, A. Saumet, C. Duret, R. Kiss et al., Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment, Pharm Res, vol.28, issue.4, p.76275, 2011.

M. Griese, Pulmonary surfactant in health and human lung diseases: state of the art, Eur Respir J, vol.13, issue.6, p.145576, 1999.

P. P. Kakade, H. K. Versteeg, G. K. Hargrave, P. Genova, W. Iii et al., Design optimization of a novel pMDI actuator for systemic drug delivery, J Aerosol Med Off J Int Soc Aerosols Med, vol.20, issue.4, p.46074, 2007.

N. Wauthoz, Développement et évaluation de formulations pour inhalation à base ancéreux dans le cadre du traitement des tumeurs pulmonaires, 2011.

G. Pilcer and K. Amighi, Formulation strategy and use of excipients in pulmonary drug delivery, Int J Pharm, vol.392, issue.12, p.119, 2010.

C. Duret, R. Merlos, N. Wauthoz, T. Sebti, F. Vanderbist et al., Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention, Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Für Pharm Verfahrenstechnik EV, vol.86, issue.1, p.4654, 2014.

N. R. Labiris and M. B. Dolovich, Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications, Br J Clin Pharmacol, vol.56, issue.6, p.58899, 2003.

K. C. Stone, R. R. Mercer, P. Gehr, B. Stockstill, and J. D. Crapo, Allometric relationships of cell numbers and size in the mammalian lung, Am J Respir Cell Mol Biol, vol.6, issue.2, p.23543, 1992.

Z. Shen, Q. Zhang, S. Wei, and T. Nagai, Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations, Int J Pharm, vol.192, issue.2, p.11521, 1999.

B. Forbes, C. G. Wilson, and M. Gumbleton, Temporal dependence of ectopeptidase expression in alveolar epithelial cell culture: implications for study of peptide absorption, Int J Pharm, vol.180, issue.2, p.22534, 1999.

P. R. Byron, Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation, J Pharm Sci, vol.75, issue.5, p.4338, 1986.

J. S. Patton, Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev, vol.19, p.336, 1996.

A. B. Gorin and P. A. Stewart, Differential permeability of endothelial and epithelial barriers to albumin flux, J Appl Physiol, vol.47, issue.6, p.131524, 1979.

G. Cevc, Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery, Crit Rev Ther Drug Carrier Syst, vol.13, issue.34, p.257388, 1996.

D. C. Klonoff, Inhaled insulin, Diabetes Technol Ther, vol.1, issue.3, p.30713, 1999.
DOI : 10.1177/1932296814555820

URL : http://europepmc.org/articles/pmc4455463?pdf=render

B. L. Laube, G. W. Benedict, and A. S. Dobs, Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulindependent diabetes mellitus, J Aerosol Med Off J Int Soc Aerosols Med, vol.11, issue.3, p.15373, 1998.

J. D. Marks, J. M. Luce, N. M. Lazar, J. N. Wu, A. Lipavsky et al., Effect of increases in lung volume on clearance of aerosolized solute from human lungs, J Appl Physiol Bethesda Md, vol.59, issue.4, p.12428, 1985.

R. Becker, S. Sha, A. D. Frick, and R. J. Fountaine, The Effect of Smoking Cessation and Subsequent Resumption on Absorption of Inhaled Insulin. Diabetes Care, vol.29, p.27782, 2006.

R. R. Henry, S. Mudaliar, W. C. Howland, N. Chu, D. Kim et al., Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care, vol.26, p.7649, 2003.

J. Hochman and P. Artursson, Mechanisms of absorption enhancement and tight junction regulation, J Controlled Release, vol.29, issue.3, p.25367, 1994.

H. T. Heidemann, J. F. Gerkens, W. A. Spickard, E. K. Jackson, and R. A. Branch, Amphotericin B nephrotoxicity in humans decreased by salt repletion, Am J Med, vol.75, issue.3, p.81, 1983.

A. Yamamoto, H. Tanaka, S. Okumura, K. Shinsako, M. Ito et al., Evaluation of insulin permeability and effects of absorption enhancers on its permeability by an in vitro pulmonary epithelial system using Xenopus pulmonary membrane, Biol Pharm Bull, vol.24, issue.4, p.3859, 2001.

B. L. Laube, The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care, vol.50, p.116176, 2005.

M. Skiba, M. .. Lahiani-skiba, M. Skiba, and . Lahiani-skiba, J. Incl. Phenom. Macrocycl. Chem, vol.75, p.3419, 2012.

S. V. Kurkov, T. Loftsson, and . Cyclodextrins, Int J Pharm, vol.453, issue.1, p.16780, 2013.

T. Loftsson and D. Duchêne, Cyclodextrins and their pharmaceutical applications, Int J Pharm, vol.329, issue.1, p.111, 2007.

J. Dutet, M. Lahiani-skiba, L. Didier, S. Jezequel, F. Bounoure et al., Nimesulide/cyclodextrin/PEG 6000 ternary complexes: physico-chemical characterization, dissolution studies and bioavailability in rats, J Incl Phenom Macrocycl Chem, vol.57, issue.14, p.2039, 2007.
DOI : 10.1007/s10847-006-9193-z

T. Järvinen, K. Järvinen, N. Schwarting, and V. J. Stella, Cyclodextrin Derivatives, SBE4CD and HPCD, Increase the Oral Bioavailability of Cinnarizine in Beagle Dogs, J Pharm Sci, vol.84, issue.3, p.2959, 1995.

J. Szejtli, Introduction and General Overview of Cyclodextrin Chemistry, Chem Rev, vol.30, issue.5, p.174354, 1998.

J. R. Moyano, M. J. Arias, J. M. Ginés, J. I. Pérez, and A. M. Rabasco, Dissolution Behavior of Oxazepam in Presence of Cyclodextrins: Evaluation of Oxazepam-Dimeb Binary Systemxs, Drug Dev Ind Pharm, vol.23, issue.4, p.37985, 1997.

G. F. Palmieri, D. Galli-angeli, G. Giovannucci, and S. Martelli, Inclusion of Methoxybutropate in -and Hydroxypropyl -Cyclodextrins: Comparison of Preparation Methods, Drug Dev Ind Pharm, vol.23, issue.1, p.2737, 1997.

G. F. Palmieri, P. Wehrlé, and A. Stamm, Inclusion of Vitamin D2 in -Cyclodextrin. Evaluation of Different Complexation Methods. Drug Dev Ind Pharm, vol.19, p.87585, 1993.

S. Fatmi, L. Bournine, M. Iguer-ouada, M. Lahiani-skiba, F. Bouchal et al., Amorphous solid dispersion studies of camptothecin-cyclodextrin inclusion complexes in PEG 6000, Acta Pol Pharm, vol.72, issue.1, p.17992, 2015.

B. Pose-vilarnovo, I. Perdomo-lópez, M. Echezarreta-lópez, P. Schroth-pardo, E. Estrada et al., Improvement of water solubility of sulfamethizole through its complexation with beta-and hydroxypropyl-beta-cyclodextrin. Characterization of the interaction in solution and in solid state, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.13, issue.3, p.32531, 2001.

J. A. Castillo, J. Palomo-canales, J. J. Garcia, J. L. Lastres, F. Bolas et al., Preparation and characterization of albendazole beta-cyclodextrin complexes, Drug Dev Ind Pharm, vol.25, issue.12, p.12418, 1999.

D. Díaz, E. Llanos, C. M. , B. Bernad, and M. J. , Study of the binding in an aqueous medium of inclusion complexes of several cyclodextrins involving fenoprofen calcium, Drug Dev Ind Pharm, vol.25, issue.1, p.10710, 1999.

M. Wulff and M. Aldén, Solid state studies of drug-cyclodextrin inclusion complexes in PEG 6000 prepared by a new method, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.8, issue.4, p.26981, 1999.

X. Ren, Y. Xue, J. Liu, K. Zhang, J. Zheng et al., A novel cyclodextrin-derived tellurium compound with glutathione peroxidase activity, Chembiochem Eur J Chem Biol, vol.3, issue.4, p.35663, 2002.
DOI : 10.1002/1439-7633(20020402)3:4<356::aid-cbic356>3.0.co;2-o

T. Loftsson, S. B. Vogensen, M. E. Brewster, and F. Konrádsdóttir, Effects of cyclodextrins on drug delivery through biological membranes, J Pharm Sci, vol.96, issue.10, p.253246, 2007.

T. Loftsson, F. Konrádsdóttir, and M. Másson, Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes, Pharm, vol.61, issue.2, p.839, 2006.

T. Loftsson and M. Masson, Cyclodextrins in topical drug formulations: theory and practice, Int J Pharm, vol.225, issue.12, p.1530, 2001.

F. Bouchal, M. Skiba, N. Chaffai, F. Hallouard, S. Fatmi et al., Fast dissolving cyclodextrin complex of piroxicam in solid dispersion part I: influence of -CD and HP-CD on the dissolution rate of piroxicam, Int J Pharm, vol.478, issue.2, p.62532, 2015.

&. Higuchi and . Connors, Phase-solubility techniques, Adv. Anal. Chem. Inst, vol.4, pp.117-211, 1965.

N. Rajagopalan, S. C. Chen, and W. Chow, A study of the inclusion complex of amphotericin-B with -cyclodextrin, Int J Pharm, vol.29, issue.23, p.1618, 1986.

D. R. Serrano, H. K. Ruiz-saldaña, G. Molero, M. P. Ballesteros, and J. J. Torrado, A novel formulation of solubilised amphotericin B designed for ophthalmic use, Int J Pharm, vol.437, issue.12, p.802, 2012.

P. Jansook and T. Loftsson, CDs as solubilizers: effects of excipients and competing drugs, Int J Pharm, vol.379, issue.1, p.3240, 2009.

M. Vikmon, A. Stadler-szöke, and J. Szejtli, Solubilization of amphotericin B with gammacyclodextrin, J Antibiot (Tokyo), vol.38, issue.12, p.18224, 1985.

H. K. Ruiz, D. R. Serrano, M. A. Dea-ayuela, P. E. Bilbao-ramos, F. Bolás-fernández et al., New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp, Int J Pharm, vol.473, issue.12, p.14857, 2014.

Y. Kim, B. Shin, V. K. Garripelli, J. Kim, E. Davaa et al., A thermosensitive vaginal gel formulation with HPgammaCD for the pH-dependent release and solubilization of amphotericin B, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.41, issue.2, p.399406, 2009.

K. K. Chakraborty and S. R. Naik, PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS, J Liposome Res, vol.11, issue.1, p.114, 2001.

M. Skiba and M. Lahiani-skiba, Novel method for preparation of cyclodextrin polymers: physico-chemical characterization and cytotoxicity, J Incl Phenom Macrocycl Chem, vol.75, issue.34, p.3419, 2013.

T. Boukhris, M. Lahiani-skiba, and M. Skiba, Novel oral formulation of cyclosporine-spray-dried dispersion using cyclodextrin copolymers, Dig J Nanomater Biostructures, 2012.

S. Joudieh, P. Bon, B. Martel, M. Skiba, and M. Lahiani-skiba, Cyclodextrin polymers as efficient solubilizers of albendazole: complexation and physico-chemical characterization, J Nanosci Nanotechnol, vol.9, issue.1, p.13240, 2009.

S. Joudieh and M. Lahiani-skiba, Letters in Drug Design and Discovery, vol.6, p.40615, 2008.

A. H. Goldberg, M. Gibaldi, and J. L. Kanig, Increasing Dissolution Rates and Gastrointestinal Absorption of Drugs Via Solid Solutions and Eutectic Mixtures I, J Pharm Sci, 1965.

, Aug, vol.1, issue.8, p.11458

R. Kriek, Palmitoylethanolamide: problems regarding micronization, ultramicronization and additives, Inflammopharmacology, vol.22, issue.3, p.1958, 2014.

J. Leleux and R. O. Williams, Recent advancements in mechanical reduction methods: particulate systems, Drug Dev Ind Pharm, vol.40, issue.3, p.289300, 2014.

L. Gao, G. Liu, J. Ma, X. Wang, L. Zhou et al., Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs, Pharm Res, vol.30, issue.2, p.30724, 2013.

C. Vo, C. Park, and B. Lee, Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs, Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV, vol.85, issue.3, p.799813, 2013.

L. S. Taylor and G. Zografi, Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions, Pharm Res, vol.14, issue.12, pp.1691-1699, 1997.

R. Ghaderi, P. Artursson, and J. Carlfors, Preparation of biodegradable microparticles using solution-enhanced dispersion by supercritical fluids (SEDS), Pharm Res, vol.16, issue.5, 1999.

K. Sekiguchi, N. Obi, Y. Ueda, . Studies, . Of et al., Chem Pharm Bull (Tokyo), vol.12, 1964.

T. Vilhelmsen, H. Eliasen, and T. Schaefer, Effect of a melt agglomeration process on agglomerates containing solid dispersions, Int J Pharm, vol.303, issue.12, p.13242, 2005.

W. L. Chiou and S. Riegelman, Preparation and dissolution characteristics of several fastrelease solid dispersions of griseofulvin, J Pharm Sci, vol.58, issue.12, p.150510, 1969.

A. P. Simonelli, S. C. Mehta, and W. I. Higuchi, Dissolution Rates of High Energy Polyvinylpyrrolidone (PVP)-Sulfathiazole Coprecipitates, J Pharm Sci, vol.58, issue.5, p.53849, 1969.

C. Brough and R. O. Williams, Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery, Int J Pharm, vol.453, issue.1, p.15766, 2013.

C. Vo, C. Park, and B. Lee, Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs, Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV, vol.85, issue.3, p.799813, 2013.

S. Jagdale, S. Patil, B. Kuchekar, and A. Chabukswar, Preparation and Characterization of Metformin Hydrochloride Compritol 888 ATO Solid Dispersion, J Young Pharm JYP, vol.3, issue.3, p.197204, 2011.

T. Boukhris, M. Lahiani-skiba, D. Martin, and M. Skiba, Pre-formulation of an oral cyclosporine free of surfactant, J Incl Phenom Macrocycl Chem, vol.75, issue.3, p.32332, 2012.
URL : https://hal.archives-ouvertes.fr/hal-01930239

M. Linn, E. Collnot, D. Djuric, K. Hempel, E. Fabian et al., Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo, Eur J Pharm Sci Off J Eur Fed Pharm Sci, vol.45, issue.3, p.33643, 2012.

E. Verhoeven, D. Beer, T. Schacht, E. Van-den-mooter, G. Remon et al., Influence of polyethylene glycol/polyethylene oxide on the release characteristics of sustained-release ethylcellulose mini-matrices produced by hot-melt extrusion: in vitro and in vivo evaluations, Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV, vol.72, issue.2, p.46370, 2009.

A. Paudel, Z. A. Worku, J. Meeus, S. Guns, and G. Van-den-mooter, Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations, Int J Pharm, vol.453, issue.1, p.25384, 2013.

D. Jang, T. Sim, and E. Oh, Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption, Drug Dev Ind Pharm, vol.39, issue.7, p.113341, 2013.

Y. Maa, P. Nguyen, T. Sweeney, S. J. Shire, and C. C. Hsu, Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying, Pharm Res, vol.16, issue.2, p.24954, 1999.

J. Kim and J. , Preparation by Spray Drying of Amphotericin B-Phospholipid Composite Particles and Their Anticellular Activity. Drug Deliv, vol.8, pp.143-150, 2001.

M. Yamaguchi, A. Ohta, T. Tsunematsu, R. Kasukawa, Y. Mizushima et al., , vol.19, p.42430

. Pj-a, Dry powder inhalers: an overview. -PubMed -NCBI, 2018.

,. Huu, J. J. Et-russotto, and R. , Guide de validation analytique. ission SFSTP. I-Méthodologie, STP Pharma Prat, vol.2, issue.4, p.205226, 1992.

, International Conference on Harmonization of Technical Requirements for the registration of pharmaceuticals for human use: Validation of analytical procedures: Q2A, Q2B, vol.2, p.2, 2006.

G. A. Morris, K. M. Jeremy, B. K. Sanders, and . Hunter, Modern NMR spectroscopy: A guide for chemists, Magn Reson Chem, vol.31, issue.12, p.10961096, 1993.

J. Matsoukas and T. Mavromoustakos, Bioactive Peptides in Drug Discovery and Design: Medical Aspects, vol.312, 1999.

S. R. Carino, D. C. Sperry, and M. Hawley, Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model, J Pharm Sci, vol.95, issue.1, p.11625, 2006.

M. Marques, R. Loebenberg, and M. Almukainzi, Simulated Biological Fluids with Possible Application in Dissolution Testing, 2016.

F. Hallouard, L. Mehenni, M. Lahiani-skiba, Y. Anouar, and M. Skiba, Solid Dispersions for Oral Administration: An Overview of the Methods for their Preparation, Curr Pharm Des, 2016.

E. J. Dufourc, I. C. Smith, and H. C. Jarrell, Interaction of amphotericin B with membrane lipids as viewed by 2H-NMR, Biochim Biophys Acta, vol.778, issue.3, p.43542, 1984.

T. J. Walsh, J. W. Hiemenz, N. L. Seibel, J. R. Perfect, G. Horwith et al., Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.26, issue.6, p.138396, 1998.

A. Akbarzadeh, R. Rezaei-sadabady, S. Davaran, S. W. Joo, N. Zarghami et al., Liposome: classification, preparation, and applications, Nanoscale Res Lett, vol.8, issue.1, p.102, 2013.

S. S. Dhule, P. Penfornis, J. He, M. R. Harris, T. Terry et al., The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma, Mol Pharm, vol.11, issue.2, p.41727, 2014.

T. J. Mcintosh, The effect of cholesterol on the structure of phosphatidylcholine bilayers, Biochim Biophys Acta, vol.513, issue.1, p.4358, 1978.

S. Lee, K. Lee, J. Kim, and S. Lim, The Effect of Cholesterol in the Liposome Bilayer on the Stabilization of Incorporated Retinol, J Liposome Res, vol.15, issue.3, p.15766, 2005.

Y. Fujii, Y. Aramaki, T. Hara, K. Yachi, H. Kikuchi et al., Enhancement of systemic and mucosal immune responses following oral administration of liposomes, Immunol Lett, vol.36, issue.1, p.659, 1993.

Y. Aramaki, H. Tomizawa, T. Hara, K. Yachi, H. Kikuchi et al., Stability of Pharm Res, vol.10, issue.8, p.122831, 1993.

S. Sundar, H. Mehta, A. V. Suresh, S. P. Singh, M. Rai et al., Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.38, issue.3, p.37783, 2004.
DOI : 10.1086/380971

URL : https://academic.oup.com/cid/article-pdf/38/3/377/822562/38-3-377.pdf

P. C. Johnson, L. J. Wheat, G. A. Cloud, M. Goldman, D. Lancaster et al., Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS, Ann Intern Med, vol.137, issue.2, p.1059, 2002.

M. Larabi, N. Pages, F. Pons, M. Appel, A. Gulik et al., Study of the toxicity of a new lipid complex formulation of amphotericin B, J Antimicrob Chemother, 2004.

D. G. Gorenstein, K. Lai, and D. O. Shah, ) and assignment of 31P signals in d(ApGpCpT)2-actinomycin D complex, Biochemistry (Mosc), vol.23, issue.26, p.671723, 1984.

N. Bloembergen and L. O. Morgan, Proton Relaxation Times in Paramagnetic Solutions. Effects of Electron Spin Relaxation, J Chem Phys, vol.34, issue.3, p.842, 2004.

, Spectroscopic studies of molecular organization of antibiotic amphotericin B in monolayers and dipalmitoylphosphatidylcholine lipid multibilayers, Biochim Biophys Acta BBA -Biomembr, vol.116, issue.11, p.1270613, 1798.

T. R. Oliveira, C. R. Benatti, and M. T. Lamy, Structural characterization of the interaction of the polyene antibiotic Amphotericin B with DODAB bicelles and vesicles, Biochim Biophys Acta, issue.11, p.262937, 1808.

S. Loew, A. Fahr, and S. May, Modeling the release kinetics of poorly water-soluble drug molecules from liposomal nanocarriers, J Drug Deliv, p.376548, 2011.

G. Lopez-berestein, M. G. Rosenblum, and R. Mehta, Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans, Cancer Drug Deliv, vol.1, issue.3, p.199205, 1984.

N. A. Hussein-al-assady, M. N. Inaam, *. Alrubayae, and E. Saad, Preparation ,Characterization and Evaluation of controlled release microspheres Containing Amphotericin B

R. Vianna, M. Bentley, G. Ribeiro, F. S. Carvalho, A. F. Neto et al., Formation of cyclodextrin inclusion complexes with corticosteroids: their characterization and stability, Int J Pharm, vol.167, issue.12, p.20513, 1998.

M. R. Bunow and I. W. Levin, Vibrational raman spectra of lipid systems containing amphotericin B, Biochim Biophys Acta BBA -Biomembr, vol.464, issue.1, p.20216, 1977.